The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1418
June 10, 2013
View Complete Issue         Table of Contents 2019 
Dimethyl Fumarate (Tecfidera) for Multiple Sclerosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dimethyl Fumarate (Tecfidera) for Multiple Sclerosis
June 10, 2013 (Issue: 1418)
The FDA has approved dimethyl fumarate (Tecfidera – Biogen Idec), formerly called BG-12, for treatment of relapsing forms of multiple sclerosis (MS). It is the third oral drug to be approved in recent years for this indication.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Dimethyl Fumarate (Tecfidera) for Multiple Sclerosis
Article code: 1418b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.